Liposomal Amphotericin B: Dosing and Monitoring Guidelines
Standard Dosing Recommendations
For invasive fungal infections, liposomal amphotericin B should be dosed at 3-5 mg/kg/day for most indications, with higher doses of 5-10 mg/kg/day reserved specifically for mucormycosis and CNS infections. 1, 2
Indication-Specific Dosing
Mucormycosis (Life-threatening):
- Start immediately at 5-10 mg/kg/day from day one—do not slowly escalate the dose 1
- For CNS involvement: Use the full 10 mg/kg/day 1
- Without CNS involvement: 5 mg/kg/day is adequate 1
- If substantial renal toxicity develops, reduce dose but avoid going below 5 mg/kg/day when possible (doses <5 mg/kg/day have only marginal evidence support) 1
Candida Infections:
- CNS candidiasis: 5 mg/kg/day 2
- Neonatal disseminated candidiasis: 3-5 mg/kg/day (use with caution, particularly with urinary tract involvement) 2
- Candidemia in adults: 3-5 mg/kg/day 2
Other Invasive Fungal Infections:
Critical Dosing Principles
- Never exceed 1.5 mg/kg for conventional amphotericin B deoxycholate (this is a different formulation with severe toxicity) 4
- Infuse over 2-6 hours depending on dose—rapid infusion causes hypotension, arrhythmias, and shock 4
- Target concentration: 0.1 mg/mL (dilute in 5% dextrose with pH >4.2) 4
- For morbidly obese patients (≥100 kg): Consider fixed dosing of 300 mg or 500 mg rather than weight-based dosing, as clearance is not affected by body size 5
Monitoring Requirements
Renal Function (Most Critical)
- Monitor serum creatinine frequently during therapy—nephrotoxicity is the primary dose-limiting toxicity 4, 6
- Risk factors for nephrotoxicity include:
Electrolytes
- Monitor magnesium and potassium regularly—amphotericin B causes renal wasting 4, 6
- Hypokalemia potentiates digitalis toxicity and enhances effects of skeletal muscle relaxants 4
- Provide prophylactic supplementation of magnesium and potassium to reduce risk 6
Other Laboratory Monitoring
- Liver function tests
- Complete blood counts and hemoglobin
- For neonates with positive Candida cultures: Perform lumbar puncture and dilated retinal examination 2
- For persistent candidemia: CT or ultrasound imaging of genitourinary tract, liver, and spleen 2
Infusion Reactions
- Acute reactions (fever, rigors, hypotension, nausea, headache, tachypnea) are common 1-3 hours after starting infusion 4
- These reactions are typically more severe with initial doses and diminish with subsequent infusions 4
- Monitor temperature, pulse, respiration, and blood pressure every 30 minutes for 2-4 hours after first dose 4
Nephrotoxicity Prevention Strategies
- Administer intravenous saline hydration prophylactically before liposomal amphotericin B 6
- Consider sodium repletion prior to administration 4
- Supplemental alkali medication may decrease renal tubular acidosis 4
- Avoid concurrent nephrotoxic medications when possible 4
- If therapy is interrupted >7 days, restart at lowest dose (0.25 mg/kg) and gradually increase 4
Important Caveats and Pitfalls
Drug Interactions to Avoid
- Separate leukocyte transfusions from amphotericin B infusions—acute pulmonary toxicity has been reported 4
- Corticosteroids and ACTH potentiate hypokalemia; if used concomitantly, closely monitor electrolytes and cardiac function 4
- Imidazoles (ketoconazole, fluconazole) may induce fungal resistance to amphotericin B; use combination therapy with caution 4
Evidence Limitations on High-Dose Therapy
Recent critical appraisal suggests that routine dose escalation beyond 5-6 mg/kg/day for mucormycosis may not improve survival and consistently increases nephrotoxicity 7. Saturable pharmacokinetics at doses >10 mg/kg/day may explain lack of additional benefit 7. However, guidelines still support 5-10 mg/kg/day based on animal models and case series showing dose-dependent efficacy 1.
When to Consider Lower Doses
For non-life-threatening invasive fungal infections in stable patients, doses as low as 1 mg/kg/day may be equally effective with lower cost and comparable toxicity 8. This applies to empiric therapy and less severe infections, but not to mucormycosis or CNS infections where higher doses are mandatory 1, 8.
Therapeutic Drug Monitoring
Routine TDM is not currently recommended for liposomal amphotericin B in children or adults—evidence is insufficient despite significant pharmacokinetic variability 9. Limited data suggest a Cmax/MIC of 25-50 for efficacy and AUC24 >600 mg·h/L for nephrotoxicity, but clinical application requires further validation 9.